Urinary Tract Infection
Patient Enrollment Begins in Exploratory Phase II Trial of NovaBay's Lead Aganocide Compound, NVC-422, in Catheter-Associated Urinary Tract Infections
Published in Women's Health Law Weekly, December 14th, 2008
NovaBay Pharmaceuticals, Inc. (AMEX: NBY, www.novabaypharma.com), a clinical stage biopharmaceutical company developing non-antibiotic, anti-infective compounds for the treatment or prevention of a wide range of bacterial, fungal and viral infections, announced that it has commenced patient enrollment in a Phase II Exploratory Study of hospitalized patients who are catheterized and have bacteriuria. This Phase II study is to explore the feasibility of developing NVC-422 as a product candidate to treat or prevent catheter-associated urinary tract infections (CAUTI).
In this open-label study, designed to evaluate the activity of NVC-422 in the bladders of patients with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
More Articles from Women's Health Law Weekly
- Ajamie Llp
Ajamie LLP's Ann Ryan Robertson Named One of 30 'Extraordinary Women in Texas Law' By Texas Lawyer - Breast Cancer Screening
The Honorable Edward M. Kennedy, Scientists Mina J. Bissell and Susan Band Horwitz, and Philanthropist Jon M. Huntsman to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight - Sinonasal Disease
Scientists at University of Nebraska discuss research in sinonasal disease - The Cochran Firm
The Cochran Firm Expands Into the Twin Cities Market - Type 2 Diabetes
New Study Data: JANUVIA (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes - Wiley-Blackwell
Mandatory HPV vaccination is unwarranted and unwise - More from this issue of Women's Health Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
